# Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

> **NCT05891119** · EARLY_PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 21 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DIETARY_SUPPLEMENT:** Caffeine
- **DRUG:** Metoprolol
- **DRUG:** Midazolam
- **DRUG:** Warfarin
- **DIETARY_SUPPLEMENT:** Vitamin K
- **DRUG:** Omeprazole
- **DRUG:** Rocatinlimab

## Key facts

- **NCT ID:** NCT05891119
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-03
- **Primary completion:** 2024-08-28
- **Final completion:** 2025-02-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891119, "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05891119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*